AZD3463 is an orally available, potent receptor tyrosine kinase (RTK) inhibtor against anaplastic lymphoma kinase ALK (Ki = 0.75 nM; IC50 = 15-21 nM with 5FAM-Srctide as substrate & 30 μM ATP), insulin-like growth factor (IGF)-1 receptor (IGF1R), ROS1 (c-Ros), and Trk-A (NTRK1). AZD3463 effectively inhibits multiple crizotinib-resistant cancer growth and displays in vivo efficacy against FLT3-ITD-dependent MOLM-13 acute myeloid leukemia (AML) as well as NGP (wt ALK) & SH-SY5Y (ALK-F1174L) neuroblastoma in mice (15 mg/kg ip.).
Orally available, potent RTK inhibtor against anaplastic lymphoma kinase (ALK), IGF1R, ROS1 and Trk-A (NTRK1) with in vitro and in vivo anticancer efficacy.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.